Pharmala Biotech Holdings Inc.

MDMA.CNCNQHealthcare● Active

$0.14

+$0.01(+3.70%)

Market Cap$15244210

P/E Ratio—

52W High$0.195

52W Low$0.085

Avg Volume208K

Open$0.13

Beta0.72

Overview

Pharmala Biotech Holdings Inc. (MDMA.CN) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

MDMA.CN · earnings · updated Jun 8, 2026

Latest Earnings

Q4 FY2023Report Date: Nov 30, 2023

EPS Actual

$0.00

Revenue

$0.00B

Fiscal Period

Q4 FY2023

FY ends December

Report Date

Nov 30, 2023

After Market Close

MDMA.CN reports quarterly as a CNQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Rev. $0.58B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

Rev. Est.$0.58B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
— Q4 FY2023	Nov 30, 2023	—	$0.00	—	$0.00B	—	—
— Q2 FY2023	May 31, 2023	—	-$0.00	—	—	—	—
— Q1 FY2023	Feb 28, 2023	—	$0.00	—	$0.00B	—	—
— Q4 FY2022	Nov 30, 2022	—	-$0.00	—	—	—	—
— Q3 FY2022	Aug 31, 2022	—	-$0.00	—	$0.00B	—	—
— Q2 FY2022	May 31, 2022	—	-$0.00	—	$0.00B	—	—
— Q1 FY2022	Feb 28, 2022	—	-$0.00	—	—	—	—
— Q4 FY2021	Nov 30, 2021	—	-$0.00	—	—	—	—

Q4 FY2023

Nov 30, 2023

EPS Actual

$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q2 FY2023

May 31, 2023

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2023

Feb 28, 2023

EPS Actual

$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q4 FY2022

Nov 30, 2022

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2022

Aug 31, 2022

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q2 FY2022

May 31, 2022

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q1 FY2022

Feb 28, 2022

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2021

Nov 30, 2021

EPS Actual

-$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for MDMA.CN.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q4 FY2023	Nov 30, 2023	—	$0.10	$0.10	+0.00%
— Q2 FY2023	May 31, 2023	—	$0.27	$0.34	+24.07%
— Q1 FY2023	Feb 28, 2023	—	$0.13	$0.14	+3.85%
— Q4 FY2022	Nov 30, 2022	—	$0.03	$0.03	-16.67%
— Q3 FY2022	Aug 31, 2022	—	$0.06	$0.05	-16.67%
— Q2 FY2022	May 31, 2022	—	$0.03	$0.03	+0.00%
— Q1 FY2022	Feb 28, 2022	—	$0.06	$0.06	+9.09%
— Q4 FY2021	Nov 30, 2021	—	No price data	$0.08	—

Q4 FY2023+0.00%

Report Date

Nov 30, 2023

EPS Beat/Miss

—

Price Before

$0.10

Price After

$0.10

Q2 FY2023+24.07%

Report Date

May 31, 2023

EPS Beat/Miss

—

Price Before

$0.27

Price After

$0.34

Q1 FY2023+3.85%

Report Date

Feb 28, 2023

EPS Beat/Miss

—

Price Before

$0.13

Price After

$0.14

Q4 FY2022-16.67%

Report Date

Nov 30, 2022

EPS Beat/Miss

—

Price Before

$0.03

Price After

$0.03

Q3 FY2022-16.67%

Report Date

Aug 31, 2022

EPS Beat/Miss

—

Price Before

$0.06

Price After

$0.05

Q2 FY2022+0.00%

Report Date

May 31, 2022

EPS Beat/Miss

—

Price Before

$0.03

Price After

$0.03

Q1 FY2022+9.09%

Report Date

Feb 28, 2022

EPS Beat/Miss

—

Price Before

$0.06

Price After

$0.06

Q4 FY2021—

Report Date

Nov 30, 2021

EPS Beat/Miss

—

Price Before

—

Price After

$0.08

Beat Rate0 / 8 quarters

Largest Move+24.07% (Q2 FY2023)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Pharmala Biotech Holdings Inc. (MDMA.CN) most recently reported earnings on November 30, 2023 for Q4 FY2023, posting EPS of $0.00 (in line with the analyst consensus of —). The next MDMA.CN earnings date is expected around September 1, 2026.

Each quarter, investors track MDMA.CN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDMA.CN revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

MDMA.CN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

MDMA.CN earnings · 4 questions

Pharmala Biotech Holdings Inc.'s next earnings report is expected around September 1, 2026. MDMA.CN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDMA.CN historically reports after market close (AMC).

MDMA.CN earnings datewhen is MDMA.CN earningsMDMA.CN next earnings datewhen does MDMA.CN report earningsMDMA.CN earnings calendar

▸ Source: FMP · Pharmala Biotech Holdings Inc. SEC filings · US GAAP · Pharmala Biotech Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026